BioSpace News Archive

Aspen Surgical Products announced today that Audax has closed on a single-asset continuation fund to support additional investment in Aspen, reaffirming its commitment to the company’s growth strategy.

Ardelyx, Inc., a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, announced the launch of IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation in adults.

Trishula Therapeutics, Inc. will be highlighted in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, LA, April 8-13, 2022.

Precigen, Inc. today announced that the FDA has granted Fast Track designation for PRGN-3006 UltraCAR-T® in patients with relapsed or refractory (r/r) AML (clinical trial identifier: NCT03927261). PRGN-3006 was previously granted FDA Orphan Drug Designation.

Ventus Therapeutics , Inc. announced today the appointment of Victor Lobanov, Ph.D., as Senior Vice President, Head of Computational Sciences.

Scorpion Therapeutics, Inc. today announced the appointment of Saurabh Saha, M.D., Ph.D. to its Board of Directors.

Clarametyx Biosciences Inc . today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating antibacterial research and development, has awarded the company an additional $3.89 million in option funding.

AngioDynamics, Inc., a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system and improving quality of life for patients, announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 21st Annual Needham Virtual Healthcare Conference at 2:15 p.m. ET on Monday, April 11, 2022.

Fluidigm Corporation announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC and Viking Global Investors LP. Fluidigm has been renamed Standard BioTools Inc. and its common stock is expected to begin trading on Nasdaq under the symbol “LAB” as of the open of market on April 6, 2022.

Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that it has closed the previously announced merger to acquire Precision Healing Inc.